M. O'shaughnessy

发表

Safety and tolerability of combination antiretroviral post-exposure prophylaxis in a population-based setting.

R. Hogg, J. Montaner, P. Braitstein, 2002, Journal of acquired immune deficiency syndromes.

Improved survival among HIV-infected individuals following initiation of antiretroviral therapy.

R. Hogg, J. Montaner, M. Schechter, 1998, JAMA.

Human immunodeficiency virus type 1 long terminal repeat variants from 42 patients representing all stages of infection display a wide range of sequence polymorphism and transcription activity

J. Montaner, I. Sadowski, A. Merzouki, 1996, Journal of virology.

A reality check: the cost of making post-exposure prophylaxis available to gay and bisexual men at high sexual risk.

R. Hogg, J. Montaner, K. Bartholomew, 2000, AIDS.

The effect of decomplementation on the infectious course of Sendai virus in mice.

R. Stewart, J. Finnie, W. Aston, 1982, Canadian Journal of Microbiology (print).

Combining pooling and alternative algorithms in seroprevalence studies

M. Schechter, J. Raboud, C. Sherlock, 1993, Journal of clinical microbiology.

Comparison of measles antihemolysin test, enzyme-linked immunosorbent assay, and hemagglutination inhibition test with neutralization test for determination of immune status

J. Weber, M. O’Shaughnessy, P. Neumann, 1985, Journal of clinical microbiology.

Industry-sponsored clinical research: a double-edged sword

J. Montaner, M. Schechter, M. O’Shaughnessy, 2001, The Lancet.

Accuracy of a saliva test for HIV antibody.

J. Montaner, S. Marion, M. O’Shaughnessy, 1995, Journal of acquired immune deficiency syndromes and human retrovirology : official publication of the International Retrovirology Association.

"Being dealt with as a whole person." Care seeking and adherence: the benefits of culturally competent care.

R. Hogg, M. O’Shaughnessy, A. Schilder, 2001, Social science & medicine.

Average Annual Drug Cost and its Determinants in a Population Based Cohort of HIV—Positive Adult Men and Women

B. Yip, R. Hogg, J. Montaner, 1998, PharmacoEconomics (Auckland).

Letters to the Editor

B. Yip, R. Hogg, J. Montaner, 1998 .

Rectal gonorrhoea as an independent risk factor for HIV infection in a cohort of homosexual men.

R. Hogg, J. Montaner, M. Schechter, 1995, Genitourinary medicine.

Learning about HIV-2

M. Schechter, M. O'shaughnessy, 1994, The Lancet.

Leaving hospital against medical advice among HIV-positive patients.

M. Schechter, A. Anis, D. Guh, 2002, CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne.

Predictors of early hospital readmission in HIV-infected patients with pneumonia

M. Schechter, A. Anis, A. Palepu, 2003, Journal of General Internal Medicine.

HIV-Positive Injection Drug Users Who Leave the Hospital Against Medical Advice: The Mitigating Role of Methadone and Social Support

M. Schechter, A. Anis, D. Guh, 2004, Journal of acquired immune deficiency syndromes.

Toronto street youth and HIV/AIDS: prevalence, demographics, and risks.

M. O’Shaughnessy, M. Fearon, S. Read, 1999, The Journal of adolescent health : official publication of the Society for Adolescent Medicine.

Patterns of sexual behavior and condom use in a cohort of homosexual men.

M. Schechter, M. O’Shaughnessy, K J Craib, 1988, American journal of public health.

Mitochondrial Toxicity in the Era of HAART: Evaluating Venous Lactate and Peripheral Blood Mitochondrial DNA in HIV-Infected Patients Taking Antiretroviral Therapy

B. Yip, R. Hogg, J. Montaner, 2003, Journal of acquired immune deficiency syndromes.

Mitochondrial:nuclear DNA ratios in peripheral blood cells from human immunodeficiency virus (HIV)-infected patients who received selected HIV antiretroviral drug regimens.

P. Harrigan, B. Yip, R. Hogg, 2003, The Journal of infectious diseases.

Changes in mitochondrial DNA as a marker of nucleoside toxicity in HIV-infected patients.

P. Harrigan, C. Alexander, J. Montaner, 2002, The New England journal of medicine.

HIV infection and risk behaviours among young gay and bisexual men in Vancouver.

R. Hogg, M. Schechter, S. Strathdee, 2000, CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne.

Surviving the sex trade: A comparison of HIV risk behaviours among street-involved women in two Canadian cities who inject drugs

M. Schechter, J. Bruneau, M. O’Shaughnessy, 2003, AIDS care.

Intensive injection cocaine use as the primary risk factor in the Vancouver HIV-1 epidemic

M. Schechter, E. Wood, S. Currie, 2003, AIDS.

Risk factors for elevated HIV incidence among Aboriginal injection drug users in Vancouver.

R. Hogg, M. Schechter, E. Wood, 2003, CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne.

Females Experiencing Sexual and Drug Vulnerabilities Are at Elevated Risk for HIV Infection Among Youth Who Use Injection Drugs

M. Schechter, M. Tyndall, Kathy Li, 2002, Journal of acquired immune deficiency syndromes.

Impact of supply-side policies for control of illicit drugs in the face of the AIDS and overdose epidemics: investigation of a massive heroin seizure.

Evan Wood, Kathy Li, Martin T Schechter, 2003, CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne.

Adherence to guidelines for the prevention of HIV-related respiratory diseases.

J. Montaner, M. Schechter, M. O’Shaughnessy, 1996, The European respiratory journal.

Needle exchange is not enough: lessons from the Vancouver injecting drug use study

Julio S. G. Montaner, M. Schechter, S. Strathdee, 1997, AIDS.

Indirect costs of HIV/AIDS mortality in Canada

R. Hogg, J. Montaner, M. Schechter, 1994, AIDS.

CD4 Cell Count Response to Nonnucleoside Reverse Transcriptase Inhibitor‐or Protease Inhibitor‐Based Highly Active Antiretroviral Therapy in an Observational Cohort Study

B. Yip, R. Hogg, J. Montaner, 2003, Journal of acquired immune deficiency syndromes.

Rates of disease progression by baseline CD4 cell count and viral load after initiating triple-drug therapy.

Julio S. G. Montaner, R. Hogg, J. Montaner, 2001, JAMA.

Depressive Symptoms Decline Among Persons on HIV Protease Inhibitors

Julio S. G. Montaner, R. Hogg, E. Wood, 2000, Journal of acquired immune deficiency syndromes.

Intermittent use of triple-combination therapy is predictive of mortality at baseline and after 1 year of follow-up

B. Yip, R. Hogg, J. Montaner, 2002, AIDS.

Decline in deaths from AIDS due to new antiretrovirals

B. Yip, R. Hogg, J. Montaner, 1997, The Lancet.

The effect of zidovudine on platelet count in HIV-infected individuals.

K. Gelmon, M. Wainberg, J. Ruedy, 1990, Journal of acquired immune deficiency syndromes.

The Vancouver Lymphadenopathy-AIDS Study: 2. Seroepidemiology of HTLV-III antibody.

B. Wiggs, M. Schechter, M. O’Shaughnessy, 1985, Canadian Medical Association journal.

Time to act: global apathy towards HIV/AIDS is a crime against humanity

R. Hogg, J. Montaner, M. Wainberg, 2002, The Lancet.

The incidence and spectrum of AIDS-defining illnesses in persons treated with antiretroviral drugs.

B. Yip, R. Hogg, J. Montaner, 1998, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Do needle exchange programmes increase the spread of HIV among injection drug users?: an investigation of the Vancouver outbreak.

M. Schechter, S. Strathdee, S. Currie, 1999, AIDS.

An anonymous seroprevalence survey of HIV infection among pregnant women in British Columbia and the Yukon Territory.

M. Schechter, S. Marion, M. O’Shaughnessy, 1990, CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne.

Evidence for a Sexually Transmitted Cofactor for AIDS-Related Kaposi's Sarcoma in a Cohort of Homosexual Men

J. Montaner, M. Schechter, C. Archibald, 1992, Epidemiology.

Risky sexual behaviours among injection drugs users with high HIV prevalence: implications for STD control

M. Schechter, M. Tyndall, Kathy Li, 2002, Sexually transmitted infections.

Antiretroviral medication use among injection drug users: two potential futures

Julio S. G. Montaner, R. Hogg, J. Montaner, 2000, AIDS.

Modern Antiretroviral Therapy Improves Life Expectancy of Gay and Bisexual Males in Vancouver’s West End

R. Hogg, K. Bartholomew, E. Wood, 2000, Canadian journal of public health = Revue canadienne de sante publique.

Barriers to use of free antiretroviral therapy in injection drug users.

B. Yip, R. Hogg, J. Montaner, 1998, JAMA.

Determinants of hospital admission among HIV-positive people in British Columbia.

R. Hogg, J. Montaner, M. O’Shaughnessy, 2000, CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne.

Socioeconomic status, access to triple therapy, and survival from HIV-disease since 1996

Evan Wood, Martin T Schechter, R. Hogg, 2002, AIDS.

The Vancouver Lymphadenopathy-AIDS Study: 6. HIV seroconversion in a cohort of homosexual men.

M. Schechter, M. O’Shaughnessy, K. Craib, 1986, CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne.

The Vancouver Lymphadenopathy-AIDS Study: 5. Antecedent behavioural, clinical and laboratory findings in patients with AIDS and HIV-seropositive controls.

M. Schechter, M. O’Shaughnessy, K. Craib, 1986, CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne.

Azithromycin prophylaxis for Mycobacterium avium complex during the era of highly active antiretroviral therapy: evaluation of a provincial program.

Julio S. G. Montaner, R. Hogg, W. Black, 2002, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Adherence to triple therapy and viral load response.

R. Hogg, J. Montaner, M. O’Shaughnessy, 2000, Journal of acquired immune deficiency syndromes.

Risk factors for Kaposi's sarcoma in the Vancouver Lymphadenopathy-AIDS Study.

M. Schechter, C. Archibald, M. O’Shaughnessy, 1990, Journal of acquired immune deficiency syndromes.

Prevalence and Response to Antiretroviral Therapy of Non-B Subtypes of HIV in Antiretroviral-Naive Individuals in British Columbia

P. Harrigan, C. Alexander, J. Montaner, 2002, Antiviral therapy.

The effects of pooling serum samples from seroconverting individuals or individuals with end stage disease for HIV antibody testing: a comparison of four screen tests and three pool sizes

J. Raboud, M. O’Shaughnessy, C. Sherlock, 1996 .

The Impact of Adherence on CD4 Cell Count Responses Among HIV-Infected Patients

P. Harrigan, B. Yip, R. Hogg, 2004, Journal of acquired immune deficiency syndromes.

Adherence to Antiretroviral Therapy and Cd4 T-Cell Count Responses among HIV-Infected Injection Drug Users

B. Yip, R. Hogg, J. Montaner, 2004, Antiviral therapy.

Expanding access to HIV antiretroviral therapy among marginalized populations in the developed world.

R. Hogg, J. Montaner, D. Bangsberg, 2003, AIDS.

Prevalence and correlates of untreated human immunodeficiency virus type 1 infection among persons who have died in the era of modern antiretroviral therapy.

R. Hogg, J. Montaner, M. Schechter, 2003, The Journal of infectious diseases.

Adherence and plasma HIV RNA responses to highly active antiretroviral therapy among HIV-1 infected injection drug users.

B. Yip, R. Hogg, J. Montaner, 2003, CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne.

Antiretroviral concentrations in untimed plasma samples predict therapy outcome in a population with advanced disease.

P. Harrigan, B. Yip, R. Hogg, 2003, The Journal of infectious diseases.

Rates of disease progression among human immunodeficiency virus-infected persons initiating multiple-drug rescue therapy.

P. Harrigan, B. Yip, R. Hogg, 2003, The Journal of infectious diseases.

Age, Adherence and Injection Drug use Predict Virological Suppression among Men and Women Enrolled in a Population-Based Antiretroviral Drug Treatment Programme

B. Yip, R. Hogg, J. Montaner, 2002, Antiviral therapy.

"Discordant" increases in CD4 cell count relative to plasma viral load in a closely followed cohort of patients initiating antiretroviral therapy.

B. Yip, R. Hogg, J. Montaner, 2002, Journal of acquired immune deficiency syndromes.

Hospital utilization and costs in a cohort of injection drug users.

M. Schechter, A. Anis, A. Palepu, 2001, CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne.

Improved survival among HIV-infected patients after initiation of triple-drug antiretroviral regimens.

R. Hogg, J. Montaner, M. Schechter, 1999, CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne.

Oral corticosteroids in patients with mild Pneumocystis carinii pneumonia and the acquired immune deficiency syndrome (AIDS).

J. Montaner, M. Schechter, J. Ruedy, 1993, Tubercle and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease.

Lipodystrophy-associated morphological, cholesterol and triglyceride abnormalities in a population-based HIV/AIDS treatment database

R. Hogg, J. Montaner, M. O’Shaughnessy, 2001, AIDS.

B. Yip, R. Hogg, J. Montaner, 2004, Quality of Life Research.

P. Harrigan, B. Yip, R. Hogg, 2004, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

No association between GB virus-C viremia and virological or immunological failure after starting initial antiretroviral therapy

P. Harrigan, R. Hogg, J. Montaner, 2002, AIDS.

Human immunodeficiency virus (HIV)/acquired immunodeficiency syndrome (AIDS) mortality in industrialized nations, 1987-1991.

R. Hogg, J. Montaner, M. Schechter, 1998, International journal of epidemiology.

Isolation of drug‐resistant variants of HIV‐1 from patients on long‐term zidovudine therapy

K. Gelmon, J. Montaner, M. Wainberg, 1989, AIDS.

One world, one hope: the cost of providing antiretroviral therapy to all nations

R. Hogg, J. Montaner, M. Schechter, 1998, AIDS.

Sources and Magnitude of Intralaboratory Variability in a Sequence-Based Genotypic Assay for Human Immunodeficiency Virus Type 1 Drug Resistance

P. Harrigan, B. Wynhoven, M. O’Shaughnessy, 2003, Journal of Clinical Microbiology.

HIV-associated risk factors among young Canadian Aboriginal and non-Aboriginal men who have sex with men

R. Hogg, M. Schechter, S. Strathdee, 1999, International journal of STD & AIDS.

Modelling the impact of HIV disease on mortality in gay and bisexual men.

R. Hogg, J. Montaner, M. Schechter, 1997, International journal of epidemiology.

Impact of HIV infection and AIDS on death rates in British Columbia and Canada.

R. Hogg, J. Montaner, M. Schechter, 1994, CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne.

Impact of HIV Infection on Mortality in a Cohort of Injection Drug Users

M. Schechter, S. Currie, M. Tyndall, 2001, Journal of acquired immune deficiency syndromes.

Influence of polymorphisms within the CX3CR1 and MDR-1 genes on initial antiretroviral therapy response

P. Harrigan, R. Hogg, J. Montaner, 2003, AIDS.

The social determinants of emergency department and hospital use by injection drug users in Canada

R. Hogg, M. Schechter, A. Anis, 1999, Journal of Urban Health.

Satellite Needle Distribution Among Injection Drug Users: Policy and Practice in Two Canadian Cities

M. Schechter, J. Bruneau, M. Tyndall, 2002, Journal of acquired immune deficiency syndromes.

A comparison of the new Federal Guidelines regulating supervised injection site research in Canada and the Tri-Council Policy Statement on Ethical Conduct for Research Involving Human Subjects

M. Schechter, E. Wood, T. Christie, 2004 .

Requiring Help Injecting as a Risk Factor for HIV Infection in

M. Schechter, E. Wood, T. Kerr, 2003 .

Requiring Help Injecting as a Risk Factor for HIV Infection in the Vancouver Epidemic

M. Schechter, E. Wood, T. Kerr, 2003, Canadian journal of public health = Revue canadienne de sante publique.

Is there a baseline CD4 cell count that precludes a survival response to modern antiretroviral therapy?

Evan Wood, P. Harrigan, B. Yip, 2003, AIDS.

Adherence to clinical guidelines for the therapeutic management of HIV disease.

J. Singer, R. Hogg, J. Montaner, 1997, Clinical and investigative medicine. Medecine clinique et experimentale.

Antiretroviral treatment patterns and incident HIV-associated morphologic and lipid abnormalities in a population-based chort.

J. Singer, R. Hogg, J. Montaner, 2002, Journal of acquired immune deficiency syndromes.

Determinants of sexual risk-taking among young HIV-negative gay and bisexual men.

R. Hogg, J. Montaner, M. Schechter, 1998, Journal of acquired immune deficiency syndromes and human retrovirology : official publication of the International Retrovirology Association.

Aetiology of AIDS

Julio S. G. Montaner, E. Vittinghoff, K. Gelmon, 1993, The Lancet.

Multiple drug rescue therapy for HIV-infected individuals with prior virologic failure to multiple regimens

P. Harrigan, B. Yip, R. Hogg, 2001, AIDS.

Full suppression of viral load is needed to achieve an optimal CD4 cell count response among patients on triple drug antiretroviral therapy

B. Yip, R. Hogg, J. Montaner, 2000, AIDS.

Effect of Medication Adherence on Survival of HIV-Infected Adults Who Start Highly Active Antiretroviral Therapy When the CD4+ Cell Count Is 0.200 to 0.350 109 cells/L

Julio S. G. Montaner, P. Harrigan, B. Yip, 2003, Annals of Internal Medicine.

Provider bias in the selection of non-nucleoside reverse transcriptase inhibitor and protease inhibitor-based highly active antiretroviral therapy and HIV treatment outcomes in observational studies

B. Yip, R. Hogg, J. Montaner, 2003, AIDS.

Antiretroviral treatment in 1998

R. Hogg, J. Montaner, J. Raboud, 1998, The Lancet.

Antiviral effect of double and triple drug combinations amongst HIV‐infected adults: lessons from the implementation of viral load‐driven antiretroviral therapy

B. Yip, R. Hogg, J. Montaner, 1998, AIDS.

Emerging international consensus for use of antiretroviral therapy

R. Hogg, J. Montaner, M. O’Shaughnessy, 1997, The Lancet.

Suppression of plasma virus load below the detection limit of a human immunodeficiency virus kit is associated with longer virologic response than suppression below the limit of quantitation.

P. Harrigan, R. Hogg, J. Montaner, 1999, The Journal of infectious diseases.

Risk factors for elevated HIV incidence rates among female injection drug users in Vancouver.

M. Schechter, E. Wood, M. Tyndall, 2002, CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne.

Incidence of hepatitis C virus infection among injection drug users during an outbreak of HIV infection

M. Schechter, S. Strathdee, S. Currie, 2022 .

Lower socioeconomic status and shorter survival following HIV infection

Julio S. G. Montaner, R. Hogg, M. Schechter, 1994, The Lancet.

Unsafe injection practices in a cohort of injection drug users in Vancouver: could safer injecting rooms help?

J. Montaner, M. Schechter, E. Wood, 2001, CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne.

Quality of life, depression and fatigue among persons co-infected with HIV and hepatitis C: Outcomes from a population-based cohort

R. Hogg, J. Montaner, M. Schechter, 2005, AIDS care.

Susceptibility to AIDS progression appears early in HIV infection

J. Montaner, M. Schechter, M. O’Shaughnessy, 1990, AIDS.

An external evaluation of a peer-run “Unsanctioned” syringe exchange program

M. Schechter, E. Wood, T. Kerr, 2003, Journal of Urban Health.

How otherwise dedicated AIDS prevention workers come to support state-sponsored shortage of clean syringes in Vancouver, Canada

M. Schechter, E. Wood, M. O’Shaughnessy, 2004 .

Needle exchange and difficulty with needle access during an ongoing HIV epidemic

R. Hogg, M. Schechter, E. Wood, 2002 .

Factors associated with persistent high-risk syringe sharing in the presence of an established needle exchange programme.

R. Hogg, J. Montaner, M. Schechter, 2002, AIDS.

Prevalence of primary HIV drug resistance among seroconverters during an explosive outbreak of HIV infection among injecting drug users.

P. Harrigan, C. Alexander, J. Montaner, 1999, AIDS.

Factors associated with frequent needle exchange program attendance in injection drug users in Vancouver, Canada.

M. Schechter, C. Archibald, M. Ofner, 1998, Journal of acquired immune deficiency syndromes and human retrovirology : official publication of the International Retrovirology Association.

Stavudine plus lamivudine in advanced human immunodeficiency virus disease: a short-term pilot study.

J. Montaner, D. Rouleau, B. Conway, 1997, The Journal of infectious diseases.

Models of survival in HIV infection and their use in the quantification of treatment benefits.

R. Hogg, J. Montaner, M. Schechter, 1998, American journal of epidemiology.

Sexual violence among a cohort of injection drug users.

R. Hogg, M. Schechter, P. Braitstein, 2003, Social science & medicine.

Impaired Virologic Response to Highly Active Antiretroviral Therapy Associated With Ongoing Injection Drug Use

B. Yip, R. Hogg, J. Montaner, 2003, Journal of acquired immune deficiency syndromes.

The end of the line: has rapid transit contributed to the spatial diffusion of HIV in one of Canada's largest metropolitan areas?

R. Hogg, J. Montaner, M. Schechter, 2000, Social science & medicine.

Characterization of Reverse Transcriptase Activity and Susceptibility to Other Nucleosides of AZT‐Resistant Variants of HIV‐1

J. Montaner, M. Wainberg, J. Ruedy, 1990, Annals of the New York Academy of Sciences.

Determinants of geographic mobility among participants in a population-based HIV/AIDS drug treatment program.

R. Hogg, J. Montaner, M. Schechter, 2000, Health & place.

Social determinants predict needle-sharing behaviour among injection drug users in Vancouver, Canada.

M. Schechter, C. Archibald, M. Ofner, 1997, Addiction.

Determinants of HIV seroconversion in drug users during a period of rising prevalence in Vancouver

M. Schechter, C. Archibald, M. Ofner, 1997 .

HIV/AIDS mortality in Canada: evidence of gender, regional and local area differentials.

R. Hogg, J. Montaner, M. Schechter, 1996, AIDS.

Access to health care and geographic mobility of HIV/AIDS patients.

R. Hogg, M. Schechter, S. Strathdee, 1995, AIDS patient care.

Interferon inhibition of autogenously induced virions (C particles) in synchronized L-929 cell cultures.

S. H. Lee, K. Easterbrook, K. Rozee, 1974, Journal of the National Cancer Institute.

Impact of HIV infection on mortality in a cohort of injection drug users.

M. Schechter, S. Currie, M. Tyndall, 2001 .

“A Lot of Things I Hide”: Understanding Disclosure in the Care of HIV-Positive Bisexual Men

R. Hogg, S. Strathdee, M. O’Shaughnessy, 1999 .

“They Don't See Our Feelings.” The Health Care Experiences of HIV-Positive Transgendered Persons

R. Hogg, M. Schechter, M. O’Shaughnessy, 1998 .

Extent to which low-level use of antiretroviral treatment could curb the AIDS epidemic in sub-Saharan Africa

Evan Wood, Paula Braitstein, Martin T Schechter, 2000, The Lancet.

Determinants of complementary therapy use in HIV-infected individuals receiving antiretroviral or anti-opportunistic agents.

R. Hogg, J. Montaner, M. Schechter, 1997, Journal of acquired immune deficiency syndromes and human retrovirology : official publication of the International Retrovirology Association.

Nontuberculous mycobacterial immune reconstitution syndrome in HIV-infected patients: spectrum of disease and long-term follow-up.

Julio S. G. Montaner, Peter Phillips, R. Hogg, 2005, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Pattern of utilization of rifabutin for prophylaxis of Mycobacterium avium complex among patients with advanced human immunodeficiency virus disease in a community setting.

R. Hogg, J. Montaner, M. Schechter, 1996, Tubercle and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease.

Depressive symptoms decline among persons on HIV protease inhibitors.

B. Yip, R. Hogg, J. Montaner, 2000 .

Do dual nucleoside regimens have a role in an era of plasma viral load-driven antiretroviral therapy?

R. Hogg, J. Montaner, M. Schechter, 1998, The Journal of infectious diseases.

HIV-1 and the aetiology of AIDS

K. Gelmon, J. Montaner, M. Schechter, 1993, The Lancet.

Highly Active Antiretroviral Therapy: Physician Experience and Enhanced Adherence to Prescription Refill

B. Yip, R. Hogg, J. Montaner, 2002, Antiviral therapy.

Antiretroviral Treatment Patterns and Incident HIV‐Associated Morphologic and Lipid Abnormalities in a Population‐Based Cohort

J. Singer, R. Hogg, J. Montaner, 2002 .

Factors associated with the response to antiretroviral therapy among HIV-infected patients with and without a history of injection drug use.

R. Hogg, J. Montaner, S. Strathdee, 2001, AIDS.

Low HIV‐1 proviral DNA burden detected by negative polymerase chain reaction in seropositive individuals correlates with slower disease progression

J. Montaner, M. Schechter, M. O’Shaughnessy, 1991, AIDS.

Purification of RBF-2, a Transcription Factor with Specificity for the Most Conserved cis-Element of Naturally Occurring HIV-1 LTRs

M. Hirst, I. Sadowski, M. O’Shaughnessy, 1999, Journal of Biomedical Science.

Purification of RBF-2, a transcription factor with specificity for the most conserved cis-element of naturally occurring HIV-1 LTRs.

M. Hirst, I. Sadowski, M. O’Shaughnessy, 1999, Journal of biomedical science.

Incidence of morphological and lipid abnormalities: gender and treatment differentials after initiation of first antiretroviral therapy.

J. Singer, R. Hogg, J. Montaner, 2002, International journal of epidemiology.

Heterogeneity of care for HIV-infected individuals decreases with the physician knowledge

R. Hogg, A. Schilder, I. Goldstone, 1996, International Journal of STD and AIDS.

A qualitative investigation into an HIV outbreak among injection drug users in Vancouver, British Columbia.

C. Archibald, M. Ofner, S. Strathdee, 1998, AIDS care.

Incarceration, Addiction and Harm Reduction: Inmates Experience Injecting Drugs in Prison

M. Schechter, M. O’Shaughnessy, P. Spittal, 2005, Substance use & misuse.

Use of pooling, and outpatient laboratory specimens in an anonymous seroprevalence survey of HIV infection in British Columbia, Canada

M. Schechter, S. Strathdee, M. O’Shaughnessy, 1995, AIDS.

The effect of cigarette smoking on lymphocyte subsets and progression to AIDS in a cohort of homosexual men.

J. Montaner, M. Schechter, R. Voigt, 1992, Clinical and investigative medicine. Medecine clinique et experimentale.

Higher baseline levels of plasma human immunodeficiency virus type 1 RNA are associated with increased mortality after initiation of triple-drug antiretroviral therapy.

P. Harrigan, B. Yip, R. Hogg, 2003, The Journal of infectious diseases.

Alcohol use and incarceration adversely affect HIV-1 RNA suppression among injection drug users starting antiretroviral therapy

B. Yip, R. Hogg, J. Montaner, 2003, Journal of Urban Health.

Hck SH3 domain‐dependent abrogation of Nef‐induced class 1 MHC down‐regulation

F. Jirik, M. O’Shaughnessy, A. Chang, 2001, European journal of immunology.

Monoclonal idiotypic and anti-idiotypic antibodies to human immunodeficiency virus type 1 envelope glycoprotein.

M. O’Shaughnessy, S. Faucher, J. Hamel, 1991, The Journal of general virology.

135 HIGH PREGNANCY RATES AND REPRODUCTIVE HEALTH INDICATORS AMONG FEMALE INJECTION DRUG USERS IN VANCOUVER, CANADA.

P. Spittal, K. Li, A. Weber, 2003, Journal of Investigative Medicine.

Another reality check: the direct costs of providing post-exposure prophylaxis in a population-based programme.

R. Hogg, J. Montaner, P. Braitstein, 2001, AIDS.

Prescribing practices in a population-based HIV postexposure prophylaxis program

R. Hogg, J. Montaner, P. Braitstein, 2002, AIDS.

Variation in plasma RNA levels, CD4 cell counts, and p24 antigen levels in clinically stable men with human immunodeficiency virus infection.

J. Montaner, M. Schechter, B. Conway, 1996, The Journal of infectious diseases.

Deadly Public Policy: What the Future Could Hold for the HIV Epidemic among Injection Drug Users in Vancouver

R. Hogg, J. Montaner, S. Strathdee, 2012, Current HIV/AIDS Reports.

Elevated rates of antiretroviral treatment discontinuation among HIV-infected injection drug users: implications for drug policy and public health

Julio S. G. Montaner, B. Yip, R. Hogg, 2004 .

Association of Phenotypic Changes in B Cell Lymphocytes and Plasma Viral Load in Human Immunodeficiency Virus-Infected Patients

J. Montaner, B. Conway, M. O’Shaughnessy, 1998, Journal of Clinical Immunology.

Modest Decreases in Nnrti Susceptibility Do Not Influence Virological Outcome in Patients Receiving Initial Nnrti-Containing Triple Therapy

K. Hertogs, W. Verbiest, B. Larder, 2002, Antiviral therapy.

HIV protease and reverse transcriptase variation and therapy outcome in antiretroviral-naive individuals from a large North American cohort

Julio S. G. Montaner, Michael V. O'Shaughnessy, P. Harrigan, 2001, AIDS.

Long-term non-progression in HIV infection

Julio S. G. Montaner, R. Hogg, M. Schechter, 1995, The Lancet.

The antiviral effect of ritonavir and saquinavir incombination amongst HIV‐infected adults: results from a community‐based study

R. Hogg, J. Montaner, M. Schechter, 1998, AIDS.

Quantitative measures of human immunodeficiency virus-specific antibodies predict progression to AIDS.

S. Strathdee, M. O’Shaughnessy, S. Read, 1995, The Journal of infectious diseases.

CCR5Δ32 and promoter polymorphisms are not correlated with initial virological or immunological treatment response

P. Harrigan, R. Hogg, J. Montaner, 2001, AIDS.

The impact of antiretroviral therapy on AIDS survival observed in a province-wide drug treatment programme.

R. Hogg, J. Montaner, M. Schechter, 1998, International journal of STD & AIDS.

Mary-Jane and her patients: sociodemographic and clinical characteristics of HIV-positive individuals using medical marijuana and antiretroviral agents.

R. Hogg, J. Montaner, P. Braitstein, 2001, AIDS.

Relation between hospital HIV/AIDS caseload and mortality among persons with HIV/AIDS in Canada.

R. Hogg, J. Montaner, M. Schechter, 1998, Clinical and investigative medicine. Medecine clinique et experimentale.

Socio-Demographic Profile and Hiv and Hepatitis C Prevalence Among Persons Who Died of a Drug Overdose

R. Hogg, E. Wood, A. Palepu, 2001 .

Modelling the Potential Economic Impact of Viral Load—Driven Triple Drug Combination Antiretroviral Therapy

B. Yip, R. Hogg, J. Montaner, 1998, PharmacoEconomics.

The Potential Public Health and Community Impacts of Safer Injecting Facilities: Evidence From a Cohort of Injection Drug Users

R. Hogg, M. Schechter, E. Wood, 2003, Journal of acquired immune deficiency syndromes.

Intentional nonadherence due to adverse symptoms associated with antiretroviral therapy.

J. Singer, R. Hogg, J. Montaner, 2002 .

Progression to AIDS and predictors of AIDS in seroprevalent and seroincident cohorts of homosexual men.

J. Montaner, M. Schechter, M. O’Shaughnessy, 1989, AIDS.

Interferon Induced Growth Depression in Diploid and Heteroploid Human Cells

S. H. Lee, K. Rozee, M. O'shaughnessy, 1972, Proceedings of the Society for Experimental Biology and Medicine. Society for Experimental Biology and Medicine.

In HIV‐infected individuals who desire combination antiviral therapy, zidovudine plus didanosine is preferred to zidovudine plus zalcitabine

M. Wainberg, J. Montaner, M. O'shaughnessy, 1994 .

The changing spectrum of AIDS index diseases in Canada

R. Hogg, J. Montaner, M. Schechter, 1994, AIDS.

A pilot study of hydroxyurea among patients with advanced human immunodeficiency virus (HIV) disease receiving chronic didanosine therapy: Canadian HIV trials network protocol 080.

J. Montaner, M. Schechter, B. Conway, 1997, The Journal of infectious diseases.

Antiretroviral therapy: 'the state of the art'.

R. Hogg, J. Montaner, M. O’Shaughnessy, 1999, Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie.

Laboratory investigation and infection control of cholera in Kingston, Ont.

I. D. Smith, H. Lior, S. Johnson, 1976, Canadian Medical Association journal.

The impact of needle-exchange programs on the spread of HIV among injection drug users: A simulation study

M. Schechter, M. Boily, J. Raboud, 2003, Journal of Urban Health.

Should we embrace new drugs with open arms? Experience from a community-based, open-arm, randomized clinical trial of combination antiretroviral therapy in advanced HIV disease.

R. Hogg, J. Montaner, M. Schechter, 1996, Journal of acquired immune deficiency syndromes and human retrovirology : official publication of the International Retrovirology Association.

Evaluation of a human immunodeficiency virus test algorithm utilizing a recombinant protein enzyme immunoassay

M. O’Shaughnessy, P. Neumann, S. Frenette, 1990, Journal of clinical microbiology.

Powassan virus encephalitis in southeastern Ontario.

M. Partington, V. Thomson, M. O'shaughnessy, 1980, Canadian Medical Association journal.